Treatment Guidelines and Regimens for Managing Patients with HIV

Opinion
Video

Sorana Segal-Maurer, MD, provides an overview of treatment guidelines for the management of patients with HIV and provides insights on currently available therapeutic regimens.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      BIC = bictegravir

      DRV = darunavir

      DTG = dolutegravir

      F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

      F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

      B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

      DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

      DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

      D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

      DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

      CAB = Cabotegravir

      CAB + RPV = Cabotegravir + Rilpivirine

      Video content above is prompted by the following questions:

      • Can you discuss the most widely used treatment guidelines to manage patients with HIV?
        • What are the differences between these regimens?
        • How do their components and pharmacodynamics impact your treatment selection?

      Newsletter

      Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

      © 2025 MJH Life Sciences

      All rights reserved.